Analysts Set Expectations for Avanos Medical FY2024 Earnings

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research cut their FY2024 EPS estimates for shares of Avanos Medical in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the company will earn $1.31 per share for the year, down from their previous forecast of $1.39. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2024 earnings at $0.39 EPS, Q2 2025 earnings at $0.40 EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.43 EPS, Q3 2026 earnings at $0.53 EPS and FY2026 earnings at $2.01 EPS.

Separately, StockNews.com lowered shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 3rd.

Avanos Medical Price Performance

NYSE AVNS opened at $18.60 on Friday. Avanos Medical has a 12 month low of $17.39 and a 12 month high of $25.36. The stock has a market cap of $854.80 million, a price-to-earnings ratio of 54.88 and a beta of 0.92. The company’s 50 day moving average is $21.84 and its two-hundred day moving average is $21.54. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AVNS. Paradice Investment Management LLC boosted its stake in Avanos Medical by 5.4% during the second quarter. Paradice Investment Management LLC now owns 1,344,949 shares of the company’s stock worth $26,791,000 after buying an additional 69,389 shares during the period. Geode Capital Management LLC boosted its stake in Avanos Medical by 1.5% during the third quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company’s stock worth $25,337,000 after buying an additional 16,065 shares during the period. Foundry Partners LLC boosted its stake in Avanos Medical by 1.1% during the third quarter. Foundry Partners LLC now owns 163,030 shares of the company’s stock worth $3,918,000 after buying an additional 1,800 shares during the period. AQR Capital Management LLC boosted its stake in Avanos Medical by 21.0% during the second quarter. AQR Capital Management LLC now owns 146,983 shares of the company’s stock worth $2,875,000 after buying an additional 25,467 shares during the period. Finally, FMR LLC boosted its stake in Avanos Medical by 34.6% during the third quarter. FMR LLC now owns 133,844 shares of the company’s stock worth $3,216,000 after buying an additional 34,421 shares during the period. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.